Nektar Therapeutics, and we continue to build on the success with significant progress in 2026. In October 2023, we began the first phase 2 study of our novel Treg biologic Respag Aldesleukin, in ...

A new study showed that among psoriasis therapies, biologics and a stepwise regimen combining phototherapy with biologics provided the greatest efficacy and quality-of-life gains, although ...

As we close 2025 and enter what we expect to be a defining year for Allogene Therapeutics, Inc., the environment around us is ...

The audited financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K contain an audit opinion from the Company’s independent registered public ...

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

Researchers have used mouse models to study how cocaine addiction alters the brain, illuminating why relapse is common as ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:30 AM EDTCompany ParticipantsAmy Parison - Senior VP ...

A modified version of psilocin could offer a way of treating certain neuropsychiatric conditions, without hallucinatory side effects.

Wall Street expects a year-over-year decline in earnings on lower revenues when Monte Rosa Therapeutics (GLUE) reports results for the quarter ended December 2025. While this widely-known consensus ...

A major obstacle is the blood-brain barrier, which Kunwar described as similar to “Saran Wrap” surrounding every blood vessel in the brain. This barrier evolved to protect the brain from foreign ...

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 ...

Waiv, a Paris-based startup, spins out of Owkin to accelerate AI-enabled precision oncology testing Waiv, a Paris-based company catalyzing AI precision testing, today announced a $33 million ...